Randomized study of rituximab (Mabthera) in patients with relapsed follicular lymphoma prior to high-dose therapy as in vivo purging and to maintain remission following high-dose therapy

Trial Profile

Randomized study of rituximab (Mabthera) in patients with relapsed follicular lymphoma prior to high-dose therapy as in vivo purging and to maintain remission following high-dose therapy

Discontinued
Phase of Trial: Phase III

Latest Information Update: 22 Jun 2016

At a glance

  • Drugs Rituximab (Primary) ; Carmustine; Cytarabine; Etoposide; Melphalan
  • Indications Follicular lymphoma
  • Focus Registrational; Therapeutic Use
  • Acronyms EBMT-LYM1
  • Most Recent Events

    • 05 Jun 2010 Five-year efficacy results presented at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO 2010).
    • 21 Aug 2007 Status change from recruiting to in progress
    • 26 Sep 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top